At the Network Biology 2.0 conference, speakers underscored the degree to which the understanding of cancer is being empowered by molecular characterization projects and is accompanied by the desire to select the right populations for clinical trials.
While RXi continues to bill itself as an RNAi drug developer, a company official indicated this week that the firm may expand its focus into the miRNA field as it works to meet its goal of defining its areas of therapeutic interest by the end of the second quarter.
American researchers reported today that they have sequenced the genomes of a primary breast tumor, brain metastasis, and matched normal tissue from an African-American woman with basal-like breast cancer as well as a xenograft sample derived from primary tumor tissue.
An Agendia official said that the company has provided "new, corrected MammaPrint reports" for all of the physicians who received faulty results and has also implemented internal quality-control measures to guard against a similar issue in the future.
Their results, detailed this month in PLoS ONE, suggest that this approach — sequencing, at a high depth, chromosomal regions identified by linkage tests — may be a good method for identifying genes in hereditary disease.
Synlab has started offering Epi proColon, Epigenomics' PCR-based blood test for early detection of colorectal cancer, through 55 German sites in its network. In addition, Epigenomics recently raised €33.1 million ($44.2 million) through a combined private and public share offering.
Ahead of a cost-effectiveness appraisal by UK's NICE, AstraZeneca is paying for EGFR mutation testing for non-small cell lung cancer patients to determine if they will benefit from treatment with Iressa. The genetic testing program is part of a patient access scheme the company has agreed to with the National Health Service to provide more granularity about the cost and value of the treatment.